Core Viewpoint - The article highlights the significant growth and transformation of China's innovative pharmaceutical industry, particularly focusing on Heng Rui Medicine's achievements and its role as a leader in this sector. The company has successfully transitioned from a follower to a leader in innovation, marking a new era of high-quality development in the industry [1][28]. Financial Performance - In the first half of 2025, Heng Rui Medicine achieved a revenue of 15.761 billion yuan, representing a year-on-year growth of 15.88% [3]. - The sales and licensing revenue from innovative drugs reached 9.561 billion yuan, accounting for 60.66% of total revenue, indicating a significant shift towards high-quality development [3]. - The net profit for the same period was 4.45 billion yuan, reflecting a year-on-year increase of 29.67%, with a net profit margin of 28.26%, marking a new high since the company's listing [5]. Research and Development - Heng Rui Medicine has maintained a high level of R&D investment, with over 6 billion yuan invested annually in the past three years, representing more than 25% of sales revenue [4]. - In the first half of 2025, R&D expenditure reached 3.871 billion yuan, supporting sustainable innovation [4]. - The company has a robust pipeline with 23 approved first-class innovative drugs and over 100 self-innovated products in clinical development [12]. Global Expansion - Heng Rui Medicine has initiated over 20 overseas clinical trials in various countries, including the US, Europe, and Japan, to promote its innovative drugs globally [16]. - The company has engaged in significant licensing agreements, including a partnership with GSK to develop up to 12 innovative drugs, with an upfront payment of 500 million USD and potential total payments of around 12 billion USD [17]. Industry Trends - The Chinese innovative pharmaceutical sector is experiencing a transformation from imitation to independent innovation, supported by favorable policies and market dynamics [19][20]. - The market for innovative drugs in China is projected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% from 2024 to 2030 [22]. - The pharmaceutical sector is viewed as a high-quality investment area, with the industry index showing a strong recovery and growth potential [25].

Group 1: Medical Insurance Development - The National Medical Insurance Bureau emphasizes the need to empower the pharmaceutical industry and implement measures to support high-quality development of innovative drugs [1][2] - By mid-2025, significant progress is expected in medical insurance, including an increase in the number of insured individuals under maternity insurance to 253 million, with expenditures reaching 67.832 billion yuan in the first half of the year [1] - The meeting highlighted the importance of direct settlement of medical expenses for drug procurement enterprises, with an average settlement cycle reduced to within 30 days [1][2] Group 2: Maternity Insurance and Long-term Care - The meeting encourages regions to include flexible employment workers, migrant workers, and new employment forms in maternity insurance coverage, while also exploring basic service packages for prenatal check-ups [3] - Long-term care insurance will be comprehensively implemented, with a focus on planning and supporting community-based care services [3] Group 3: Healthcare System Reform - The meeting calls for the reform of medical service pricing and the expansion of immediate settlement of medical insurance funds to healthcare institutions [2] - There is a push for the integration of technology in medical insurance, transitioning from passive payment to proactive empowerment and health investment [3]

Group 1 - The core point of the news is that China Europe Fund announced a limit on daily subscriptions for the China Europe Medical Innovation Fund to 100,000 yuan starting from August 11, 2025, to ensure stable fund operations and protect the interests of fund shareholders [1][2][3] - The China Europe Medical Innovation Fund, managed by fund manager Ge Lan, was established in February 2019 and primarily invests in stocks related to medical innovation [3][4] - As of mid-2023, the fund's total net asset value exceeded 8.2 billion yuan, with major investments in healthcare and manufacturing sectors, accounting for 46.41% and 41.99% of the total assets, respectively [5][6] Group 2 - The top ten holdings of the fund include companies such as Sanofi Pharmaceutical, Keren Biotechnology, and Kangfang Biotech, with the largest holding, Sanofi Pharmaceutical, showing a year-to-date increase of nearly 400% [4][6] - The fund's unit net value has been rising, reaching 1.6874 yuan, compared to a low of below 0.9 yuan a year ago [7][8] - The fund's outlook for the third quarter highlights optimism in the innovative drug sector, with expectations for global collaboration and important clinical data disclosures, as well as ongoing domestic policy support for high-quality drug development [8]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Viewpoints - The report highlights a positive outlook on innovative drugs and emphasizes the importance of the upstream supply chain [5][22]. - The recent measures introduced by the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs, which includes increasing support for R&D and enhancing the role of commercial insurance in the multi-tiered medical security system [4][21]. Summary by Sections 1. Market Performance Review - From July 7 to July 11, 2025, the Shenwan Pharmaceutical and Biological Index increased by 1.82%, outperforming the CSI 300 Index by 1.00 percentage points, ranking 16th among 31 Shenwan first-level industry indices [2][12]. - Year-to-date, the Shenwan Pharmaceutical and Biological Index has risen by 12.11%, surpassing the CSI 300 Index by 10.08 percentage points, ranking 4th among the 31 indices [14][17]. 2. Important Events - The recent introduction of 16 measures to support the high-quality development of innovative drugs includes enhancing R&D support, facilitating access to basic medical insurance and commercial health insurance, and improving payment capabilities for innovative drugs [4][21]. 3. Industry Insights - The report emphasizes the growing role of commercial insurance in the multi-tiered medical security system, which is expected to provide greater flexibility and support for high-priced innovative drugs and medical devices [5][22]. - The innovative drug sector is entering a phase of realization of results, with significant R&D progress expected to drive investment in 2025 [22]. - The report suggests focusing on companies involved in overseas expansion, particularly in emerging markets, as they present substantial growth potential [22]. - The ongoing acceleration of centralized procurement in various pharmaceutical sectors is anticipated to lead to new growth opportunities, particularly in insulin and orthopedic segments [22].

Report Summary 1. Industry Investment Rating No industry investment rating is provided in the report. 2. Core Views - The market interprets the "anti - involution" policy as a price rebound rather than a reversal. Stocks in coal, transportation, and steel industries led the decline, while those in electronics, power equipment, and pharmaceutical biology industries led the rise. The semi - annual report pre - increase theme is a visible investment line until mid - July. In the high - level oscillation period, it is advisable to focus on arbitrage opportunities by going long on far - month contracts and short on near - month contracts in the stock index futures market [1][6]. - In the stock index options market, due to low trading liquidity and volatility, and the potential ineffectiveness of sentiment indicators, it is recommended to adopt a covered defense strategy [2][6]. - In the treasury bond futures market, the short - end performed better than the long - end. The long - end bullish sentiment weakened marginally. In the short term, the bond market is expected to continue to oscillate due to factors such as the central bank's cautious liquidity injection, high local bond supply in July, and potential tariff disturbances [2][7][8]. 3. Summary by Directory 3.1 Market Views - **Stock Index Futures** - **Data**: IF, IH, IC, IM's current - month basis points were - 21.47, - 16.95, - 48.66, - 63.24 respectively, with changes of 1.22, 2.6, - 12.31, - 15.95 points compared to the previous trading day; the current - month to next - month spreads were 18.6, 4.6, 54.2, 71.8 points respectively, with changes of 0.8, - 0.8, 3.8, - 1.6 points; the positions changed by - 481, - 1877, 1566, 2566 lots respectively [6]. - **Logic**: The market interprets the "anti - involution" policy as a price rebound. After excluding inflation - chain investment opportunities, funds rotate among scattered hot industries. There is a lack of a main line to boost trading volume during the high - level oscillation period [6]. - **Operation Suggestion**: Hold a wait - and - see attitude [6]. - **Stock Index Options** - **Data**: The trading volume of the options market rebounded slightly, but the overall trading liquidity remained low. The implied volatility of CSI 1000 index options dropped by 0.39%, and that of SSE 500 ETF options decreased by 0.18% [2][6]. - **Logic**: The double - low situation of liquidity and volatility, combined with the ineffective sentiment indicators, indicates that the index has resistance above and the market will continue to oscillate [2][6]. - **Operation Suggestion**: Adopt a covered defense strategy [2][6]. - **Treasury Bond Futures** - **Data**: The trading volumes of T, TF, TS, TL's current - quarter contracts were 64924, 51486, 24843, 72609 lots respectively, with 1 - day changes of 6969, 5555, - 101, 3741 lots; the positions were 206020, 156476, 115715, 117980 lots respectively, with 1 - day changes of - 499, - 1347, 120, - 1737 lots. Other spread and basis data are also provided [7]. - **Logic**: The long - end bullish sentiment weakened marginally due to the stock - bond seesaw effect and the profit - taking motivation of long - end futures. The central bank may be cautious in liquidity injection, and the local bond supply in July may be high, limiting the downward space of interest rates. Tariff disturbances may increase after July 9 [2][7][8]. - **Operation Suggestion**: Maintain an oscillating trend strategy; pay attention to short - hedging at low basis levels; appropriately focus on basis widening; the mid - term strategy of steepening the yield curve has higher odds [8]. 3.2 Economic Calendar - The official manufacturing PMI in China in June was 49.7, up from 49.5 in the previous month. The final value of the US Markit manufacturing PMI in June was 52.9, higher than the expected and previous values. The US unemployment rate in June was 4.1%, lower than the expected 4.3% and the previous 4.2%, and the non - farm payrolls increased by 14.7 million, higher than the expected 10.6 million [9]. 3.3 Important Information and News Tracking - **Domestic Macro**: On July 3, the Minister of the Ministry of Industry and Information Technology hosted a manufacturing enterprise symposium, where 14 photovoltaic enterprises and industry association representatives exchanged views on various aspects and put forward policy suggestions [9]. - **Overseas Macro**: The US non - farm payrolls increased by 14.7 million in June, higher than expected, and the unemployment rate dropped to 4.1%. The private - sector employment increased by only 7.4 million, the lowest since last October, mainly driven by the healthcare industry [10]. 3.4 Derivatives Market Monitoring - The report mentions the monitoring of stock index futures, stock index options, and treasury bond futures data, but specific data details are not fully presented in the provided content [11][15][27].

Group 1 - Barclays Bank is the largest holder of the newly listed Hong Kong innovative drug ETF, holding 20 million shares, which accounts for 4.5997% of the total fund shares [2][3] - The innovative drug sector has seen a significant rebound since the end of 2024, with the Hang Seng Innovative Drug Index rising nearly 68% year-to-date as of July 2 [7] - The recent policy measures from the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs, proposing 16 measures to enhance R&D support and improve market accessibility [7][8] Group 2 - In the past, Barclays also held a significant position in the Huatai-PineBridge Hang Seng Innovative Drug ETF, owning 85 million shares, which represented 42.02% of the total shares, with a return of over 56% since its inception [4][2] - Recent trends show that the top holders of other innovative drug ETFs are primarily brokerages, private equity, individual investors, and corporate pension plans, indicating a diverse investor base [5] - The innovative drug industry in China is at a critical turning point, with a focus on ADC and dual-antibody technologies, which are expected to capture significant market share in global immunotherapy [8]

Core Insights - The National Healthcare Security Administration (NHSA) announced that the medical insurance fund expenditure for negotiated drugs will exceed 100 billion yuan during the 2024 agreement period [1] - The number of approved innovative Class 1 drugs in China has significantly increased, reaching 48 in 2024, which is more than five times the number in 2018; nearly 40 have been approved in the first half of this year, indicating a surge in approvals [1] - The "Several Measures to Support the High-Quality Development of Innovative Drugs" outlines 16 initiatives across five areas to enhance support for innovative drug research and development, inclusion in medical insurance, clinical application, payment capabilities, and organizational guarantees [1] Industry Developments - The NHSA emphasizes the need to support true innovation and differentiated innovation in the biopharmaceutical industry to avoid excessive competition and homogenization of products [1] - There is a focus on providing necessary medical insurance data services to support innovative drug research while ensuring data security and compliance [1] Medical Insurance Access - The NHSA is negotiating with innovative drug companies to establish medical insurance payment standards, creating a multi-dimensional value assessment system centered on patient health benefits [2] - For cases involving the reasonable use of innovative drugs within the medical insurance directory, medical institutions are supported in independently reporting special cases when standard disease-based payments are not suitable [2] - Innovative drugs listed in commercial health insurance directories will not be included in the basic medical insurance self-payment rate indicators, allowing for more flexible payment arrangements [2]

Investment Rating - The industry investment rating is positive, with expectations of overall returns exceeding the CSI 300 index by more than 5% in the next six months [11]. Core Insights - The introduction of the "Measures to Support the High-Quality Development of Innovative Drugs" marks a significant opportunity for the innovative drug sector, addressing key challenges in research, payment, and clinical application [4][8]. - The report emphasizes a comprehensive support system for innovative drug development, including the use of national health insurance data to guide research directions and enhance innovation efficiency [5]. - The measures aim to optimize the inclusion of innovative drugs in the basic medical insurance catalog and commercial health insurance, ensuring that they meet clinical value and market conditions [6][9]. - The report highlights the potential for innovative drugs to expand their market reach, both domestically and internationally, under the Belt and Road Initiative, enhancing accessibility for patients [9]. Summary by Sections Industry Ratings - Sub-industry ratings for chemical pharmaceuticals, traditional Chinese medicine, and biopharmaceuticals are currently not rated [3]. Recommended Companies and Ratings - Companies such as Kelun-Botai, Kangfang Biotech, Lepu Biotech, Maiwei Biotech, and Ailis are expected to experience a new round of high-quality development opportunities, maintaining a "buy" rating [9].

Group 1 - The core viewpoint of the articles is the support for the development of innovative drugs in China, as outlined in the measures released by the National Healthcare Security Administration and the National Health Commission, which include 16 specific initiatives to enhance the entire chain of innovative drug research and development, access, hospital use, and multi-payment systems [1] - The innovative drug sector has shown strong performance, with the Sci-Tech Innovation Pharmaceutical ETF (588860) achieving a trading volume of 33.04 million yuan on average over the past six months, ranking first among comparable funds [1] - The Sci-Tech Innovation Pharmaceutical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which consists of 50 large-cap companies in the biopharmaceutical and related sectors, reflecting the overall performance of representative companies in the innovative pharmaceutical industry [1] Group 2 - The Sci-Tech Innovation Pharmaceutical ETF (588860) is characterized by high elasticity, with potential index fluctuations of up to 20%, focusing on medical innovation devices and innovative drugs, and has the lowest management and custody fees among similar ETFs at 0.45% and 0.07% respectively [2] - Domestic innovative drug companies are entering a harvest phase after years of R&D investment, with recent favorable policies and increasing overseas licensing amounts contributing to performance growth [2] - The market outlook remains positive for innovative drug companies with true innovation capabilities, as they are expected to have greater valuation elasticity, while cyclical recovery presents opportunities in upstream sectors like CXO and scientific services [2] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (ICBC, 159217) closely tracks the National Index of Hong Kong Stock Connect Innovative Drugs, with a management fee of 0.40% and a custody fee of 0.07%, both among the lowest in its category [3] - The tracking error of the Hong Kong Stock Connect Innovative Drug ETF over the past two months is 0.8395%, indicating a strong alignment with its benchmark index [3]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical industry [1] Core Insights - The report discusses the issuance of 16 supportive policies by the National Healthcare Security Administration and the National Health Commission aimed at enhancing the high-quality development of innovative drugs [3] - It emphasizes a comprehensive support system that includes research and development, market access, payment mechanisms, and clinical application to transition China from a "generic drug powerhouse" to an "innovative drug stronghold" [8] Summary by Sections Research and Development - Data empowerment and the introduction of patient capital are expected to reduce the risks associated with innovative drug development [4] - The policy guidance aims to lower the backend risks of innovative drug research and development [4] Market Access and Payment - The dual drive of medical insurance and commercial insurance is set to expand market opportunities [5] - The dynamic adjustment mechanism for the medical insurance catalog will shorten the time gap between drug approval and market entry [7] - The introduction of a commercial health insurance catalog for innovative drugs will diversify the payment system for high-end innovative drugs [7] Clinical Application - The report highlights the optimization of processes and diversified guarantees to facilitate the final stages of drug application [6] - Encouragement for medical institutions to expedite the use of innovative drugs post-catalog updates is expected to enhance the speed of drug deployment in clinical settings [7] Investment Recommendations - The report suggests focusing on leading innovative drug companies and specialized biotech firms, including 恒瑞医药 (Hengrui Medicine), 信达生物 (Innovent Biologics), 康诺亚 (CanSino Biologics), 药明康德 (WuXi AppTec), and 凯莱英 (Kelun) [8]